Evidence map›Paper›PMID 41140271›Full record

ArticleThe Journal of antimicrobial chemotherapy2025

Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999-2019).

Carolyne Horner, Rosy Reynolds, Shazad Mushtaq, Aiysha Chaudhry, Rachael Adkin, Michael Allen, Christopher Longshaw, Benjamin J Parcell, David M Livermore

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carolyne HornerBritish Society for Antimicrobial Chemotherapy, 53 Regent Place, Birmingham B1 3NJ, UK.
Rosy ReynoldsBritish Society for Antimicrobial Chemotherapy, 53 Regent Place, Birmingham B1 3NJ, UK.
Shazad MushtaqAntimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency, Colindale, London NW9 5EQ, UK.ORCID 0000-0002-3908-8332
Aiysha ChaudhryAntimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency, Colindale, London NW9 5EQ, UK.
Rachael AdkinAntimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency, Colindale, London NW9 5EQ, UK.
Michael AllenBritish Society for Antimicrobial Chemotherapy, 53 Regent Place, Birmingham B1 3NJ, UK.
Christopher LongshawBritish Society for Antimicrobial Chemotherapy, 53 Regent Place, Birmingham B1 3NJ, UK.ORCID 0000-0002-5586-7256
Benjamin J ParcellDivision of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
David M LivermoreAntimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency, Colindale, London NW9 5EQ, UK.

Funding

AbbottAstellasAstraZenecaAventisBasileaBayerBritish Society for Antimicrobial ChemotherapyCempraCerexaCubistGeneSoftGSKJohnson & JohnsonMelintaMSDNabrivaNovartisOscientPfizerReplidyneRib-XTheravanceWyeth
6 · The paper itself

Abstract

objectivesThis study aimed to report the serotype distribution of Streptococcus pneumoniae isolates from UK and Irish patients with bacteraemia or community-associated lower respiratory tract infections (CA-LRTI). Depending upon the year, these were from 23 to 39 sentinel laboratories and were collected between 1999 and 2019, thus spanning the introduction of pneumococcal conjugate vaccines, PCV7 and PCV13.

methodsPneumococcal identification, susceptibility testing and serotyping were undertaken by a central laboratory. Changes in serotype distributions and among the predominant types showing antibiotic non-susceptibility were reviewed in relation to vaccine deployment.

resultsFollowing the introduction of PCV7 (2006) and PCV13 (2010), major shifts occurred in serotype prevalence for both bacteraemia and CA-LRTI. PCV7 types and most PCV13 types (but not 3 and 19A) were largely or wholly displaced. Many of the displaced types (e.g. 6B, 9V, 14, 19F and 23B) had been internationally prevalent and were associated with antibiotic resistance. Other serotypes-many included within the older pneumococcal polysaccharide vaccine, PPV23-expanded into the space, with serotype 8 becoming especially prominent in bacteraemia, though not respiratory infections. Further increasingly prevalent types included 9N, 10A, 12F and 22F. Serotype 15A, often multi-resistant, rose then fell in relative importance after deployment of PCV13. Among the currently most prevalent types, serotype 3 is rarely resistant to agents besides tetracyclines and bloodstream serotype 8 isolates mostly are fully susceptible.

conclusionsThese data offer a comparison of serotypes associated with bacteraemia and respiratory disease over two decades in the UK and Ireland.

Indexed as

Drug Resistance, BacterialPneumococcal InfectionsStreptococcus pneumoniaeAdolescentAdultAgedAnti-Bacterial AgentsBacteremiaChildChild, PreschoolCommunity-Acquired InfectionsFemaleHeptavalent Pneumococcal Conjugate VaccineHumansInfantIreland13-valent pneumococcal vaccineAnti-Bacterial AgentsHeptavalent Pneumococcal Conjugate VaccinePneumococcal Vaccines

Identifiers

PMID41140271
PMCPMC12556646

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.